Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.
Journal: Cancer cell
Published: August 01, 2025
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 18, 2025
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies.
Journal: Journal of hematology & oncology
Published: January 06, 2025
Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.
Journal: PloS one
Published: January 04, 2024
A bootstrapping method to optimize go/no-go decisions from single-arm, signal-finding studies in oncology.
Journal: CPT: pharmacometrics & systems pharmacology
Published: October 12, 2023
Showing 1-6 of 6
Last Updated: 09/26/2026